A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson’s disease. The study has identified the role of protein LRRK2 in tuberculosis, results have shown that it behaves similarly in Parkinson disease. This finding could pave the way for advance treatments for both diseases. A mutation in LRRK2 gene is common in Parkinson’s patients and LRRK2 blockers are showing promise against it. However, the exact mechanism of how this mutation causes the disease is still unknown. Currently, there are drugs based on LRRK2 for treating Parkinson’s that could be repurposed for Tuberculosis. Drug resistant TB is on the rise and Bacille-Calmette-Guérin (BCG) is the only WHO-approved TB vaccine that shows variable efficacy in adults, due Researchers are continuously searching for more effective treatment options.
DelveInsight Blog
Related Article
![pharma-news-for-alnylam-bms-daichii-sankyo-vertex pharma-news-for-alnylam-bms-daichii-sankyo-vertex](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/25155241/pharma-news-for-alnylam-bms-daichii-sankyo-vertex.png)
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Find More![pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/18150914/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png)
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval
Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...
Find More![pharma-news-for-moderna-almirall-lilly-ipsen pharma-news-for-moderna-almirall-lilly-ipsen](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/11141344/pharma-news-for-moderna-almirall-lilly-ipsen.png)
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!